Abstract:Several neurodevelopmental and neurodegenerative disorders affecting the central nervous system are potentially treatable via viral vector-mediated gene transfer. Adeno-associated viral (AAV) vectors have been used in clinical trials because of their desirable properties including a high degree of safety, efficacy, and stability. Major factors affecting tropism, expression level, and cell type specificity of AAV-mediated transgenes include encapsidation of different AAV serotypes, promoter selection, and the timing of vector administration. In this study, we evaluated the ability of single-stranded AAV2 vectors pseudotyped with viral capsids from serotype 9 (AAV2/9) to transduce the brain and target gene expression to specific cell types after intracerebroventricular injection into mice. Titer-matched AAV2/9 vectors encoding the enhanced green fluorescent protein (eGFP) reporter, driven by the cytomegalovirus (CMV) promoter, or the neuron-specific synapsin-1 promoter, were injected bilaterally into the lateral ventricles of C57/BL6 mice on postnatal day 5 (neonatal) or 21 (juvenile). Brain sections were analyzed 25 days after injection, using immunocytochemistry and confocal microscopy. eGFP immunohistochemistry after neonatal and juvenile administration of viral vectors revealed transduction throughout the brain including the striatum, hippocampus, cerebral cortex, and cerebellum, but with different patterns of cell-specific gene expression. eGFP expression was seen in astrocytes after treatment on postnatal day 5 with vectors carrying the CMV promoter, expanding the usefulness of AAVs for modeling and treating diseases involving glial cell pathology. In contrast, injection of AAV2/9-CMV-eGFP on postnatal day 21 resulted in preferential transduction of neurons. Administration of AAV2/9-eGFP with the synapsin-1 promoter on either postnatal day 5 or 21 resulted in widespread neuronal transduction. These results outline efficient methods and tools for gene delivery to the nervous system by direct, early postnatal administration of AAV vectors. Our findings highlight the importance of promoter selection and age of administration on the intensity, distribution, and cell type specificity of AAV transduction in the brain.

Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression

A humanized mouse model for adeno-associated viral gene therapy

Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Enhancer AAVs for targeting spinal motor neurons and descending motor pathways in rodents and macaque

Identification of cis-regulatory modules for adeno-associated virus-based cell-type-specific targeting in the retina and brain

Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species

Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice

Stereotactic Delivery of Helper-dependent Adenoviral Viral Vectors at Distinct Developmental Time Points to Perform Age-dependent Molecular Manipulations of the Mouse Calyx of Held

Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain

Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System

Selective transgene expression in cerebellar Purkinje cells and granule cells using adeno-associated viruses together with specific promoters

An evolved AAV variant enables efficient genetic engineering of murine T cells

Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog

A Simple and Efficient Method for in Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Preparation of Raav9 to Overexpress or Knockdown Genes in Mouse Hearts

Expression-based selection identifies a microglia-tropic AAV capsid for direct and CSF routes of administration in mice

Common AAV gene therapy vectors show indiscriminate transduction of living human brain cell types

Adeno-associated Virus Vector Enables Safe and Efficient Cas9 Activation in Neonatal and Adult Cas9 Knockin Murine Cochleae

A Comprehensive Atlas of AAV Tropism in the Mouse

Identification of &Lt;i>cis</i>-Regulatory Modules for Aav-Based Cell Type-Specific Targeting in the Retina and Brain